Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:2:p1
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 2 (pt 1/16)
Character Range: 120839–123794

Schedule 2—Pharmacy medicines

Note: See section 16, subsection 54(1) and section 58.
ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80% of acetic acid (CH3COOH) for therapeutic use.
ACETYLCYSTEINE in preparations for oral use except when labelled with a recommended daily dose of 1 g or less of acetylcysteine.
ACONITUM spp. for therapeutic use in adults:

       (a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids; or

       (b) in preparations for dermal use containing 0.02% or less of total alkaloids, in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids.
    ALIMEMAZINE when combined with one or more other therapeutically active substances in solid oral preparations when:
 (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
 (b) in a day‑night pack containing alimemazine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;
 except in preparations for the treatment of children under 2 years of age.
ALOXIPRIN.
AMOROLFINE in preparations for topical use except in preparations for the treatment of tinea pedis.
ANTAZOLINE in eye drops.
ASPIRIN except when:

       (a) included in Schedule 4, 5 or 6; or

       (b) in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent other than when combined with an effervescent agent, that are:

          (i) enclosed in a primary pack that contains 12 or less individually wrapped powders or sachets of granules; and

          (ii) compliant with the requirements of the required advisory statements for medicine labels; or

       (c) in tablets or capsules containing aspirin as the only therapeutically active constituent other than when combined with an effervescent agent, that are:

          (i) either:

             (A) packed in blister or strip packing; or

             (B) in a container with a child-resistant closure; and

          (ii) either:

             (A) in a primary pack that contains not more than 25 tablets or capsules, each containing 325 mg or less of aspirin; or

             (B) in a primary pack that contains not more than 16 tablets or capsules, each containing 500 mg or less of aspirin; or

             (C) in a primary pack that contains not more than 100 tablets or capsules, each containing 100 mg or less of aspirin, and that is labelled for the prevention of cardiovascular disease or for the inhibition of platelet aggregation; and

          (iii) compliant with the requirements of the required advisory statements for medicine labels.
    ASTODRIMER SODIUM when used in a nasal spray.
    ATROPA BELLADONNA (belladonna):
 (a) for external use